Table 3 Clinical characteristics and healthcare resource utilization in the concurrent period by FVC% change group
By lung-function change category (based on relative change in FVC%)a | ||||||
|---|---|---|---|---|---|---|
Stable [A] | Marginal [B] | Significant [C] | Relative effect measure (95 % CI) | |||
(N = 250) | (N = 98) | (N = 142) | [C] vs. [A] | [C] vs. [B] | [B] vs. [A] | |
6-Month IR per Patient | IRR | |||||
Rate of suspected AEx | 0.21 | 0.25 | 0.25 | 1.20 (0.69–2.09) | 1.00 (0.55–1.82) | 1.20 (0.63–2.28) |
6-Month Risk | OR | |||||
Risk of suspected AEx | 14.1 % | 16.7 % | 20.4 % | 1.56 (0.78–3.15) | 1.27 (0.56–2.91) | 1.23 (0.56–2.70) |
Risk of progression | 23.4 % | 38.7 % | 48.6 % | 3.09 (1.67–5.72) | 1.50 (0.75–3.00) | 2.07 (1.07–3.97) |
6-Month IR per Patient | IRR | |||||
Rate of IPF-related outpatient visits | 1.85 | 1.95 | 1.78 | 0.96 (0.82–1.12) | 0.91 (0.75–1.12) | 1.05 (0.87–1.27) |
Unscheduled and/or urgent care | 0.16 | 0.23 | 0.22 | 1.42 (0.64–3.15) | 0.97 (0.48–1.96) | 1.46 (0.76–2.80) |
For a suspected AEx | 0.17 | 0.19 | 0.19 | 1.16 (0.58–2.31) | 1.04 (0.52–2.09) | 1.11 (0.54–2.29) |
Rate of IPF-related ER visits | 0.18 | 0.16 | 0.14 | 0.81 (0.31–2.11) | 0.87 (0.37–2.01) | 0.94 (0.40–2.17) |
For a suspected AEx | 0.04 | 0.02 | 0.05 | 1.15 (0.34–3.86) | 2.46 (0.41–14.72) | 0.47 (0.07–3.17) |
Rate of IPF-related hospitalizations | 0.06 | 0.08 | 0.05 | 0.80 (0.20–3.12) | 0.59 (0.17–1.98) | 1.36 (0.35–5.20) |
For a suspected AEx | 0.04 | 0.06 | 0.04 | 0.96 (0.19–4.82) | 0.63 (0.17–2.32) | 1.52 (0.27–8.60) |
Rate of hospital days | 0.39 | 0.48 | 0.25 | 0.63 (0.10–3.82) | 0.52 (0.10–2.62) | 1.22 (0.28–5.26) |
Rate of ICU stays | 0.03 | 0.03 | 0.02 | 0.59 (0.07–4.97) | 0.47 (0.07–2.95) | 1.25 (0.21–7.58) |
Rate of ICU days | 0.08 | 0.18 | 0.07 | 0.79 (0.05–12.62) | 0.36 (0.03–4.05) | 2.16 (0.23–20.59) |